News

InvestorsHub on MSN3d
Sarepta shares drop after EU regulators reject Elevidys gene therapy
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European ...
Sarepta Shares Fall After EU Regulator Rejects Gene Therapy
Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment ...
BioSpace3d
Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Investing.com South Africa3d
Sarepta stock falls after Elevidys fails to get backing by EU regulators
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
FiercePharma1mon
FDA investigates patient deaths after treatment with Sarepta's Duchenne ...
FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys By Angus Liu Jun 25, 2025 10:26am Sarepta Therapeutics gene therapy U.S. FDA FDA investigation ...